Skip to main navigation Skip to search Skip to main content

Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions

  • the Chronic Nonbacterial Osteomyelitis/Chronic Recurrent Multifocal Osteomyelitis Study Group and the Childhood Arthritis and Rheumatology Research Alliance Scleroderma, Vasculitis, Autoinflammatory and Rare Diseases Subcommittee
  • University of Washington
  • University of North Carolina at Chapel Hill
  • Stanford University
  • Children's Mercy
  • Levine Children's Hospital
  • Tel Aviv University
  • University of Utah
  • Duke University
  • Hackensack Meridian Health
  • Emory University
  • Hospital for Special Surgery - New York
  • Beth Israel Deaconess Medical Center
  • University of Calgary
  • McMaster Children's Hospital
  • National Institutes of Health
  • University of Vermont
  • Goryeb Children's Hospital
  • Hacettepe University
  • Vivantes Children's Hospital in Friedrichshain
  • University of Toronto
  • Boston Children's Hospital
  • Technische Universität Dresden
  • Alder Hey Children's NHS Foundation Trust
  • University of Iowa

Research output: Contribution to journalArticlepeer-review

191 Scopus citations

Abstract

Objective: To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO), to enable comparative effectiveness treatment studies. Methods: Virtual and face-to-face discussions and meetings were held within the CNO/CRMO subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). A literature search was conducted, and CARRA membership was surveyed to evaluate available treatment data and identify current treatment practices. Nominal group technique was used to achieve consensus on treatment plans for CNO refractory to nonsteroidal antiinflammatory drug (NSAID) monotherapy and/or with active spinal lesions. Results: Three consensus treatment plans (CTPs) were developed for the first 12 months of therapy for CNO patients refractory to NSAID monotherapy and/or with active spinal lesions. The 3 CTPs are methotrexate or sulfasalazine, tumor necrosis factor inhibitors with optional methotrexate, and bisphosphonates. Short courses of glucocorticoids and continuation of NSAIDs are permitted for all regimens. Consensus was achieved on these CTPs among CARRA members. Consensus was also reached on subject eligibility criteria, initial evaluations that should be conducted prior to the initiation of CTPs, and data items to collect to assess treatment response. Conclusion: Three consensus treatment plans were developed for pediatric patients with CNO refractory to NSAIDs and/or with active spinal lesions. Use of these CTPs will provide additional information on efficacy and will generate meaningful data for comparative effectiveness research in CNO.

Original languageEnglish
Pages (from-to)1228-1237
Number of pages10
JournalArthritis Care and Research
Volume70
Issue number8
DOIs
StatePublished - Aug 2018

Fingerprint

Dive into the research topics of 'Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions'. Together they form a unique fingerprint.

Cite this